Trial Profile
Phase II randomized double-blinded trial of SGN-00101 [verpasep caltespen] (HSP-E7) for treatment of CIN II/III [grade II or III cervical intraepithelial neoplasia].
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2010
Price :
$35
*
At a glance
- Drugs Verpasep caltespen (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 23 Sep 2005 New trial record.